Vertex Pharmaceuticals executive Duncan McKechnie reported multiple stock transactions. On February 25, 2026, he made open-market sales of 2,500 common shares at $486.35 per share and 2,410 shares at $489.00 per share.
On February 24, 2026, 873 shares were disposed of at $485.11 per share to cover tax obligations by delivering shares. After these transactions, he directly owned 17,559 Vertex common shares. The filing notes the sales were made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported a Form 4 transaction involving a tax-withholding disposition of 3,547 shares of common stock at $485.11 per share on February 24, 2026. After this transaction, he directly owned 34,797 shares and indirectly held 440 shares through a 401(k) plan.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a tax-related share transaction. On this Form 4, she had 4,981 shares of common stock withheld at $485.11 per share to cover taxes, a type of non-market disposition. After this, she directly owned 138,278 shares of Vertex common stock.
Vertex Pharmaceuticals executive Mark E. Bunnage reported two stock dispositions. On February 25, 2026, he completed an open-market sale of 620 shares of common stock at an average price of $486.35 per share. After this sale, he directly held 7,284 shares.
On February 24, 2026, he disposed of 582 shares at an average price of $485.11 per share to cover tax obligations, rather than as an open-market sale. The transactions were made under a company-approved Rule 10b5-1 trading plan that Dr. Bunnage entered into on November 26, 2025.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On February 24, 2026, she transferred 1,453 shares of Vertex common stock at an indicated price of $485.11 per share to cover tax obligations by delivering shares rather than cash. After this tax-withholding transaction, she directly owned 40,063 Vertex common shares.
Vertex Pharmaceuticals EVP and Chief Legal Officer Jonathan Biller sold 945 shares of common stock on February 25, 2026 at $486.35 per share in an open-market trade under a Rule 10b5-1 plan entered on February 24, 2025. On February 24, 2026, 1,144 shares were also disposed of to cover tax withholding, leaving 13,659 directly owned shares.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported share sales under a pre-set trading plan. On February 25, 2026, he completed an open-market sale of 668 shares of common stock at $486.35 per share, leaving 18,432 shares held directly afterward.
On February 24, 2026, he disposed of 1,627 shares at $485.11 per share to cover tax obligations by delivering shares, a non-open-market transaction. These transactions were made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on August 11, 2025.
Vertex Pharmaceuticals senior executive Kristen Ambrose reported two stock transactions. As SVP & Chief Accounting Officer, she sold 223 shares of Vertex common stock in an open-market sale at an average price of $486.35 per share under a company-approved Rule 10b5-1 trading plan.
She also disposed of 546 shares at $485.11 per share to cover tax obligations by delivering shares rather than cash. After these transactions, she directly held 6,981 shares of Vertex common stock.
Fidelity Brokerage Services LLC filed a Form 144 reporting a proposed sale of common shares of Vertex Pharmaceuticals. The notice lists multiple grant/purchase dates and share lots tied to ESPP purchases and restricted stock vesting, including a line showing 2,394,365 (units) and an NASDAQ listing reference. The filing enumerates specific lot dates and share counts that the filer may sell under Rule 144.
Ourania Tatsis submitted a Form 144 notice reporting a proposed sale related to 260 shares of common stock. The filing lists multiple open‑market dispositions by the same person during the prior three months, including 4,500 shares on 12/03/2025 and 4,500 shares on 01/07/2026, with dollar amounts shown for each trade.